Paxlovid Rebound Proven in Prospective Study
Virologic and Symptomatic Rebound >20% at 28 Days
By Peter A. McCullough, MD, MPH
The US Centers for Disease Control placed a public health advisory on Pfizer’s flagship oral COVID-19 drug, Paxlovid on May 24, 2022 based a a few case reports of viral rebound.
A new prospective randomized trial by Yang and colleagues confirmed shockingly high rates of virologic 21.1% and symptomatic 24.5% rebound at 28 days. In this study Paxlovid was found to be no better than mindeudesivir (VV116) which is essentially an oral form of remdesivir.
These data have important implications: 1) rebound with Paxlovid is unacceptably high at 28 days and is prolonging the infection, worsening the duration of spread, 2) mindeudesivir (VV116) has the same problem. It appears patients are much better off with the McCullough Protocol using a choice of drugs (other than Paxlovid) in combination to resolve the syndrome rapidly without risk of rebound.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Paxlovid and Remdesevir. Two names I have already learned to stay far away from.
So much for the pricey pharma alternatives. Stick with IVM and all things the CDC and Fauci worked so hard to discredit and keep away from you. Thank you Dr McCullough, and Drs Kory, Marik, Urso, Mercola, Zelenko and all FLCCC doctors.